to those of other drugs approved for the treatment of AUD such as naltrexone (Srisurapanont and Jarusuraisin, 2005) and acamprosate (Carmen et al., 2004). Early reports of VAR-induced altered behavior, which resulted in a 2015 FDA warning regarding the use of VAR, were not substantiated and the FDA revised the warning in 2016 and stated that VAR does not pose serious mental health risks. Importantly, there appears to be minimal side effects of VAR reported in individuals with AUD (McKee et al., 2009; Mitchell et al., 2012, Verplaetse et al., 2016a, 2016b).
